Key Takeaways
- • Hedge funds have increased bullish exposure to U.S. healthcare stocks to nearly the highest level in five years, driven by gains in equipment, supplies, life-sciences tools, and pharmaceuticals, according to Goldman Sachs analysis.
- • The S&P 500 healthcare index gained approximately 5% during 2026, significantly outpacing European healthcare stocks which rose roughly 2%, signaling regional preference for U.S. healthcare assets.
- • Healthcare deal volume is projected to reach $173 billion in 2026, the highest annual level since 2019, with smaller pharmaceutical companies accepting larger valuation discounts for acquisition certainty.
- • Specialist healthcare hedge funds generated returns approaching 40% between August 2025 and April 2026, substantially outperforming generalist equity-trading hedge funds at approximately 17% over the same period.
- • Hedge fund positioning reflects expectations for AI-assisted drug discovery gains, accelerated FDA review processes, and increased corporate transaction activity, with new drug approvals in 2025 reaching the highest annual level since 2020.
Summary
Hedge funds have substantially increased their bullish positioning in U.S. healthcare stocks, with Goldman Sachs noting that exposure levels are now approaching five-year highs. Managers have added healthcare exposure for a second consecutive week, establishing positions across healthcare equipment and supplies, life-sciences tools, and pharmaceutical companies. This heightened activity reflects multiple tailwinds in the sector, including improved research productivity driven by artificial-intelligence-assisted drug discovery, active financing markets, and expected corporate transactions.
The performance divergence between U.S. and European healthcare markets underscores investor preference for domestic healthcare exposure. The S&P 500 healthcare index has gained nearly 5% during 2026, substantially outpacing the approximate 2% increase in related European healthcare stocks. Goldman Sachs projects healthcare deal volume will reach $173 billion during 2026, marking the highest annual level since 2019. This activity is partly driven by smaller pharmaceutical companies' willingness to accept larger valuation discounts in exchange for acquisition certainty, according to Felix Lo, portfolio manager at Trium Capital.
Regulatory developments have created a mixed environment for healthcare investors. The FDA accelerated its review processes, while new drug approvals in 2025 reached the highest annual level since 2020. However, Lo noted that regulatory volatility surrounding drug approvals has increased during 2026, introducing uncertainty into the investment landscape. Despite this volatility, specialist healthcare hedge funds have significantly outperformed broader market strategies, generating returns approaching 40% between August 2025 and April 2026, compared with approximately 17% for generalist equity-trading hedge funds over the same period.
The performance divergence between U.S. and European healthcare markets underscores investor preference for domestic healthcare exposure. The S&P 500 healthcare index has gained nearly 5% during 2026, substantially outpacing the approximate 2% increase in related European healthcare stocks. Goldman Sachs projects healthcare deal volume will reach $173 billion during 2026, marking the highest annual level since 2019. This activity is partly driven by smaller pharmaceutical companies' willingness to accept larger valuation discounts in exchange for acquisition certainty, according to Felix Lo, portfolio manager at Trium Capital.
Regulatory developments have created a mixed environment for healthcare investors. The FDA accelerated its review processes, while new drug approvals in 2025 reached the highest annual level since 2020. However, Lo noted that regulatory volatility surrounding drug approvals has increased during 2026, introducing uncertainty into the investment landscape. Despite this volatility, specialist healthcare hedge funds have significantly outperformed broader market strategies, generating returns approaching 40% between August 2025 and April 2026, compared with approximately 17% for generalist equity-trading hedge funds over the same period.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.